| scholarly article | Q13442814 |
| P50 | author | James Wilson | Q16947166 |
| P2093 | author name string | Adam Bagg | |
| Frank S Lee | |||
| Guang-ping Gao | |||
| Mark L Batshaw | |||
| Narendra Chirmule | |||
| Nelson A Wivel | |||
| Steven E Raper | |||
| P2860 | cites work | Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis | Q28268241 |
| The acute respiratory distress syndrome | Q29615140 | ||
| Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. | Q33337331 | ||
| A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency | Q33340517 | ||
| Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes | Q33903377 | ||
| Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy | Q35232341 | ||
| Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses | Q35837026 | ||
| The pathogenesis of sepsis | Q37251283 | ||
| Patient selection may affect gene therapy success. Dominant negative effects observed for ornithine transcarbamylase in mouse and human hepatocytes | Q37351823 | ||
| Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses | Q39879953 | ||
| Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial | Q40586745 | ||
| Infections and the inflammatory response in acute respiratory distress syndrome | Q40651722 | ||
| Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors | Q40942254 | ||
| Update on the mechanisms of immune suppression of injury and immune modulation | Q41004765 | ||
| Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? | Q41210322 | ||
| Adenovirus-mediated transfer of human factor IX gene in immunodeficient and normal mice: evidence for prolonged stability and activity of the transgene in liver | Q41245959 | ||
| The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia | Q41354708 | ||
| MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. | Q41664847 | ||
| Liver transplantation for the treatment of urea cycle disorders | Q41926237 | ||
| Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses. | Q42676162 | ||
| Activation of coagulation after administration of tumor necrosis factor to normal subjects | Q43690695 | ||
| Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector | Q43693238 | ||
| Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration | Q45863202 | ||
| Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver | Q45874045 | ||
| Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors | Q45876696 | ||
| Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages | Q45877053 | ||
| Adenovirus-mediated in vivo gene transfer rapidly protects ornithine transcarbamylase-deficient mice from an ammonium challenge | Q45881297 | ||
| Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver | Q45889223 | ||
| Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse. | Q45889451 | ||
| Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. | Q53916620 | ||
| Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. | Q54563329 | ||
| Persistence of Replication-Deficient Adenovirus-Mediated Gene Transfer in Lungs of Immune-Deficient (nu/nu) Mice | Q61456119 | ||
| Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector | Q64378881 | ||
| Mosaicism for an intragenic deletion in a boy with mild ornithine transcarbamylase deficiency | Q69837464 | ||
| Postinjury multiple organ failure: a bimodal phenomenon | Q71039840 | ||
| Pattern of soluble TNF receptors I and II in sepsis | Q71585158 | ||
| Early predictors of postinjury multiple organ failure | Q72703617 | ||
| Release of anti-inflammatory mediators after major torso trauma correlates with the development of postinjury multiple organ failure | Q73440283 | ||
| P433 | issue | 1-2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Adenoviridae | Q193447 |
| inflammation | Q101991 | ||
| patient | Q181600 | ||
| systemic inflammatory response syndrome | Q776030 | ||
| P304 | page(s) | 148-58 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Molecular Genetics and Metabolism | Q6895949 |
| P1476 | title | Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer | |
| P478 | volume | 80 |
| Q54461045 | A Comparative Safety Profile Assessment of Oncolytic Virus Therapy Based on Clinical Trials. |
| Q27484994 | A Heterologous DNA Prime-Venezuelan Equine Encephalitis Virus Replicon Particle Boost Dengue Vaccine Regimen Affords Complete Protection from Virus Challenge in Cynomolgus Macaques |
| Q92020423 | A Molecular Revolution in the Treatment of Hemophilia |
| Q36098953 | A concise peer into the background, initial thoughts and practices of human gene therapy |
| Q33258821 | A look to future directions in gene therapy research for monogenic diseases |
| Q37150738 | A myeloid cell-binding adenovirus efficiently targets gene transfer to the lung and escapes liver tropism |
| Q57367323 | A nanogel with passive targeting function and adjustable polyplex surface properties for efficient anti-tumor gene therapy |
| Q24599954 | A new generation of human artificial chromosomes for functional genomics and gene therapy |
| Q37590085 | A new link between virus cell entry and inflammation: adenovirus interaction with integrins induces specific proinflammatory responses |
| Q40478238 | A nonviral vector with transfection activity comparable with adenoviral transduction. |
| Q33945612 | A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice |
| Q35641856 | A novel and simple method for rapid generation of recombinant porcine adenoviral vectors for transgene expression |
| Q33586974 | A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology |
| Q40479387 | A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. |
| Q45872533 | A polymerase chain reaction-based methodology to detect gene doping |
| Q59352404 | A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs) |
| Q36920480 | A rapid Q-PCR titration protocol for adenovirus and helper-dependent adenovirus vectors that produces biologically relevant results. |
| Q45879506 | A realistic chance for gene therapy in the near future |
| Q38954393 | A reduction in the human adenovirus virion size through use of a shortened fibre protein does not enhance muscle transduction following systemic or localised delivery in mice. |
| Q40403870 | A remarkable permeability of canalicular tight junctions might facilitate retrograde, non-viral gene delivery to the liver via the bile duct |
| Q40011736 | A simple, lanthanide-based method to enhance the transduction efficiency of adenovirus vectors |
| Q38651271 | A snapshot of biologic drug development: Challenges and opportunities |
| Q45875379 | A syringe-focused ultrasound device for simultaneous injection of DNA and gene transfer |
| Q36410697 | A theranostic small interfering RNA nanoprobe protects pancreatic islet grafts from adoptively transferred immune rejection |
| Q35027496 | AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects |
| Q34716958 | AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models |
| Q35686509 | ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells |
| Q42412771 | Absence of systemic immune response to adenovectors after intraocular administration to children with retinoblastoma |
| Q21134608 | Activation of P2X(7) receptor by ATP plays an important role in regulating inflammatory responses during acute viral infection |
| Q35791792 | Adeno-Associated Virus-Mediated Gene Transfer to Renal Tubule Cells via a Retrograde Ureteral Approach |
| Q38981492 | Adeno-associated virus 8-mediated gene therapy for choroideremia: preclinical studies in in vitro and in vivo models |
| Q38188560 | Adeno-associated virus structural biology as a tool in vector development |
| Q34317131 | Adeno-associated virus-mediated gene transfer |
| Q39303013 | Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. |
| Q40357603 | Adenoviral GDNF gene transfer enhances neurofunctional recovery after recurrent laryngeal nerve injury. |
| Q37967604 | Adenoviral load diagnostics by quantitative polymerase chain reaction: techniques and application |
| Q40424880 | Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma |
| Q30370445 | Adenoviral vectors as novel vaccines for influenza. |
| Q39654400 | Adenoviral vectors stimulate innate immune responses in macrophages through cross-talk with epithelial cells |
| Q34977219 | Adenovirus |
| Q33389860 | Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. |
| Q28084476 | Adenovirus membrane penetration: Tickling the tail of a sleeping dragon |
| Q39065475 | Adenovirus serotype 11 causes less long-term intraperitoneal inflammation than serotype 5: implications for ovarian cancer therapy |
| Q64376894 | Adenovirus toxicity and tropism in vivo: not as simple as A,B,C (or D,E,F) |
| Q39706964 | Adenovirus vector delivery stimulates natural killer cell recognition. |
| Q27001601 | Adenovirus vectors for gene therapy, vaccination and cancer gene therapy |
| Q89606305 | Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial |
| Q41699782 | Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine |
| Q38187126 | Adenovirus-triggered innate signalling pathways |
| Q37951524 | Adenovirus-vectored drug-vaccine duo as a potential driver for conferring mass protection against infectious diseases |
| Q38295771 | Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls |
| Q36132288 | Adenoviruses for treatment of cancer |
| Q37335982 | Adenoviruses increase endothelial cell proliferation, migration, and tube formation: partial reversal by the focal adhesion kinase inhibitor, FRNK. |
| Q27011815 | Adipocytes as a vehicle for ex vivo gene therapy: Novel replacement therapy for diabetes and other metabolic diseases |
| Q54342284 | Advances in the management of disseminated adenovirus disease in stem cell transplant recipients: impact of adenovirus load (DNAemia) testing. |
| Q37118764 | An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression |
| Q37144360 | An overview of biochemical genetics |
| Q96302902 | An overview of development in gene therapeutics in China |
| Q37863587 | An update on gene therapy in Parkinson's disease |
| Q40815226 | Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors |
| Q33558337 | Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models |
| Q45874236 | Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits |
| Q35628601 | Apoptin-modified human mesenchymal stem cells inhibit growth of lung carcinoma in nude mice |
| Q91866605 | Applications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy |
| Q37355005 | Aquaporin-1 gene transfer to correct radiation-induced salivary hypofunction |
| Q36790320 | Arthritis gene therapy's first death |
| Q40439258 | Augmentation of transgene expression in cold-preserved organs using vascular endothelial growth factor receptor-mediated adenoviral vector combined with hyperbaric oxygen |
| Q50519704 | Baculovirus as delivery system for gene transfer during hypothermic organ preservation. |
| Q36298627 | Balloon catheter delivery of helper-dependent adenoviral vector results in sustained, therapeutic hFIX expression in rhesus macaques |
| Q51857382 | Beyond Gene Delivery: Strategies to Engineer the Surfaces of Viral Vectors. |
| Q39342777 | Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses |
| Q33803963 | Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging |
| Q40091715 | Biodistribution and safety profile of recombinant adeno-associated virus serotype 6 vectors following intravenous delivery. |
| Q37176436 | Biological approaches to ischemic tissue repair: gene- and cell-based strategies |
| Q90259836 | Biomaterial-guided delivery of gene vectors for targeted articular cartilage repair |
| Q92339833 | Biosafety, and improvement of osteoporosis in cage layers through using chOPG protein |
| Q36695688 | CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness |
| Q33687979 | CR1/2 is an important suppressor of Adenovirus-induced innate immune responses and is required for induction of neutralizing antibodies |
| Q98771286 | CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future |
| Q98292026 | CRISPR-Cas9-Mediated In Vivo Gene Integration at the Albumin Locus Recovers Hemostasis in Neonatal and Adult Hemophilia B Mice |
| Q33632925 | CRISPR/Cas9: Transcending the Reality of Genome Editing |
| Q39294371 | CRISPR/Cas9: at the cutting edge of hepatology. |
| Q33711997 | Calcium gluconate in phosphate buffered saline increases gene delivery with adenovirus type 5. |
| Q46467541 | Can ultrasound solve the transport barrier of the neural retina? |
| Q40329093 | Canine adenovirus vectors for lung-directed gene transfer: efficacy, immune response, and duration of transgene expression using helper-dependent vectors. |
| Q42424335 | Capsid-modified adenoviral vectors for improved muscle-directed gene therapy |
| Q27014770 | Cardiovascular gene therapy for myocardial infarction |
| Q36040801 | Cationic lipid-DNA complexes for non-viral gene therapy: relating supramolecular structures to cellular pathways |
| Q33257608 | Cationic liposome-DNA complexes: from liquid crystal science to gene delivery applications |
| Q36251313 | Cell transplantation for diabetes |
| Q36272601 | Cell-specific targeting of lipid-based carriers for ODN and DNA. |
| Q36473038 | Cellular and genetic therapies for haemophilia |
| Q33265007 | Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect |
| Q34607182 | Cellular immune response against firefly luciferase after sleeping beauty-mediated gene transfer in vivo |
| Q50977875 | Challenges and Prospects for Helper-Dependent Adenoviral Vector-Mediated Gene Therapy. |
| Q37849777 | Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease |
| Q64378490 | Characterization of hemodynamic events following intravascular infusion of recombinant adenovirus reveals possible solutions for mitigating cardiovascular responses |
| Q26995655 | Circumventing antivector immunity: potential use of nonhuman adenoviral vectors |
| Q35558172 | Clinical review: gene-based therapies for ALI/ARDS: where are we now? |
| Q64375676 | Cloning of carrier cells infected with oncolytic adenovirus driven by midkine promoter and biosafety studies |
| Q36495546 | Clostridial spores as live 'Trojan horse' vectors for cancer gene therapy: comparison with viral delivery systems. |
| Q27332110 | Coagulation factor X activates innate immunity to human species C adenovirus |
| Q64378634 | Coagulation factor defends adenovirus from immune attack |
| Q37980864 | Cocaine hydrolase gene therapy for cocaine abuse |
| Q34389675 | Combined cocaine hydrolase gene transfer and anti-cocaine vaccine synergistically block cocaine-induced locomotion. |
| Q33659517 | Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors |
| Q36600228 | Combining cell therapy and nanotechnology |
| Q37309252 | Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. |
| Q45865539 | Congenital muscular dystrophy: mini-agrin delivers in mice |
| Q34977697 | Construction of a novel expression cassette for increasing transgene expression in vivo in endothelial cells of large blood vessels |
| Q36969510 | Contrasting features of urea cycle disorders in human patients and knockout mouse models |
| Q37676230 | Correction of Monogenic and Common Retinal Disorders with Gene Therapy |
| Q34774816 | Correction of hyperbilirubinemia in gunn rats using clinically relevant low doses of helper-dependent adenoviral vectors |
| Q64930555 | Current Landscape of Heart Failure Gene Therapy. |
| Q37841547 | Current options and new developments in the treatment of haemophilia |
| Q35881934 | Current status and prospects for gene therapy |
| Q36823697 | Current status of cardiovascular gene therapy |
| Q38862302 | Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world |
| Q35667739 | Current status of immunotherapy for the treatment of lung cancer. |
| Q38184158 | DNA cleavage enzymes for treatment of persistent viral infections: recent advances and the pathway forward. |
| Q36250777 | DNA-based therapeutics and DNA delivery systems: a comprehensive review |
| Q38321960 | De novo formed satellite DNA-based mammalian artificial chromosomes and their possible applications |
| Q40256121 | Decreased Vector Gene Expression from E2b Gene-Deleted Adenovirus Serotype 5 Vaccines Intensifies Proinflammatory Immune Responses |
| Q38912667 | Delivering Nucleic-Acid Based Nanomedicines on Biomaterial Scaffolds for Orthopedic Tissue Repair: Challenges, Progress and Future Perspectives |
| Q37677605 | Delivering the goods: viral and non-viral gene therapy systems and the inherent limits on cargo DNA and internal sequences |
| Q38356303 | Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE. |
| Q27007011 | Design and application of multifunctional DNA nanocarriers for therapeutic delivery |
| Q37299072 | Designing heart performance by gene transfer. |
| Q38003108 | Detection of EPO gene doping in blood |
| Q33637630 | Development of a gene transfer-based treatment for radiation-induced salivary hypofunction |
| Q36065953 | Development of mammalian artificial chromosomes for the treatment of genetic diseases: Sandhoff and Krabbe diseases |
| Q26823376 | Developments in the treatment of hemophilia B: focus on emerging gene therapy |
| Q38145327 | Diagnosis and treatment of adenovirus infection in immunocompromised patients |
| Q33835146 | Direct gene therapy for bone regeneration: gene delivery, animal models, and outcome measures. |
| Q34652434 | Dual gene expression in embryoid bodies derived from human induced pluripotent stem cells using episomal vectors |
| Q37664701 | Durable expression of minicircle DNA-liposome-delivered androgen receptor cDNA in mice with hepatocellular carcinoma |
| Q35684857 | Ebola virus glycoproteins: guidance devices for targeting gene therapy vectors |
| Q40528538 | Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats |
| Q30436033 | Effect of nonviral plasmid delivered basic fibroblast growth factor and low intensity pulsed ultrasound on mandibular condylar growth: a preliminary study. |
| Q39842450 | Effect of sonoporation on cationic liposome-mediated IFNbeta gene therapy for metastatic hepatic tumors of murine colon cancer |
| Q39491840 | Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer |
| Q37925857 | Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies |
| Q45008585 | Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia. |
| Q52431143 | Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9 |
| Q41782046 | Efficient gene delivery vectors by tuning the surface charge density of amino acid-functionalized gold nanoparticles |
| Q34999733 | Efficient gene transfer and durable transgene expression in grafted rabbit veins |
| Q33267297 | Efficient non-viral ocular gene transfer with compacted DNA nanoparticles |
| Q33713289 | Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates |
| Q45061679 | Electroporation-mediated transfer of plasmid DNA encoding IL-10 attenuates orthotopic tracheal allograft stenosis in rats. |
| Q50187342 | Elixir of Life: Thwarting Aging With Regenerative Reprogramming |
| Q89603279 | Emerging patent landscape for non-viral vectors used for gene therapy |
| Q36960845 | Emerging strategies for cell and gene therapy of the muscular dystrophies |
| Q37822290 | Emerging therapeutic approaches in the management of retinal angiogenesis and edema. |
| Q36967723 | Emerging therapies for mitochondrial disorders |
| Q36764543 | Encapsulation of nucleic acids and opportunities for cancer treatment |
| Q37567831 | Engineered adenovirus serotypes for overcoming anti-vector immunity |
| Q39077630 | Engineered retroviral virus-like particles for receptor targeting |
| Q38150365 | Engineering protein self-assembling in protein-based nanomedicines for drug delivery and gene therapy. |
| Q37380704 | Enhanced bone morphogenic protein adenoviral gene delivery to bone marrow stromal cells using magnetic nanoparticle |
| Q38938407 | EpCAM-targeted liposomal si-RNA delivery for treatment of epithelial cancer. |
| Q40379092 | Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination |
| Q38738678 | Equine performance genes and the future of doping in horseracing. |
| Q45885660 | Eradication of hepatocellular carcinoma xenografts by radiolabelled, lipiodol-inducible gene therapy |
| Q38874665 | Ethical considerations and challenges in first-in-human research |
| Q33799990 | Evaluation of signal transduction pathways after transient cutaneous adenoviral gene delivery. |
| Q26775030 | Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going? |
| Q31114544 | Expression and secretion of human proinsulin-B10 from mouse salivary glands: implications for the treatment of type I diabetes mellitus |
| Q89540000 | Expression of Neprilysin in Skeletal Muscle by Ultrasound-Mediated Gene Transfer (Sonoporation) Reduces Amyloid Burden for AD |
| Q38647828 | Expression of apolipoprotein A-I in rabbit carotid endothelium protects against atherosclerosis |
| Q39946262 | Extended release of adenovirus from silica implants in vitro and in vivo |
| Q36715322 | Extracorporeal delivery of rAAV with metabolic exchange and oxygenation |
| Q45875328 | Factors influencing retention of adenovirus within tumours following direct intratumoural injection. |
| Q36305902 | Fatal coma in a young adult due to late-onset urea cycle deficiency presenting with a prolonged seizure: a case report |
| Q35434767 | Fluorescence microscopy colocalization of lipid-nucleic acid nanoparticles with wildtype and mutant Rab5-GFP: A platform for investigating early endosomal events |
| Q38119906 | From gene engineering to gene modulation and manipulation: can we prevent or detect gene doping in sports? |
| Q37696495 | Future of cell and gene therapies for Parkinson's disease |
| Q38199215 | GLP-1-mediated gene therapy approaches for diabetes treatment |
| Q30439944 | GammadeltaT cells initiate acute inflammation and injury in adenovirus-infected liver via cytokine-chemokine cross talk |
| Q33891559 | Gene Therapy 2017: Progress and Future Directions |
| Q91610685 | Gene Therapy Today and Tomorrow |
| Q28595868 | Gene Therapy for Metabolic Diseases |
| Q37470623 | Gene and cell therapy for heart failure |
| Q38000390 | Gene delivery to bone |
| Q37171838 | Gene doping: the hype and the reality. |
| Q33691825 | Gene expression in lung and liver after intravenous infusion of polyethylenimine complexes of Sleeping Beauty transposons |
| Q36532106 | Gene therapeutics: the future of brain tumor therapy? |
| Q37669606 | Gene therapies development: slow progress and promising prospect |
| Q35904004 | Gene therapy applications of viral vectors |
| Q28083399 | Gene therapy approaches to regenerating the musculoskeletal system |
| Q41465719 | Gene therapy as a treatment concept for inherited retinal diseases |
| Q80448411 | Gene therapy for arthritis |
| Q35117004 | Gene therapy for bone healing |
| Q35040146 | Gene therapy for cancer treatment: past, present and future |
| Q36800517 | Gene therapy for cardiac arrhythmias: a dream soon to come true? |
| Q26799437 | Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation |
| Q38059008 | Gene therapy for cardiovascular disease: perspectives and potential |
| Q38132253 | Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium |
| Q83556143 | Gene therapy for heart failure |
| Q38073152 | Gene therapy for heart failure: where do we stand? |
| Q37015311 | Gene therapy for inborn errors of liver metabolism: progress towards clinical applications |
| Q40153924 | Gene therapy for laryngeal paralysis |
| Q37346064 | Gene therapy for liver enzyme deficiencies: what have we learned from models for Crigler-Najjar and tyrosinemia? |
| Q37781788 | Gene therapy for liver regeneration: experimental studies and prospects for clinical trials. |
| Q36226708 | Gene therapy for malignant glioma: current clinical status |
| Q45877752 | Gene therapy for metabolic disorders: an overview with a focus on urea cycle disorders. |
| Q33881920 | Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. |
| Q35160142 | Gene therapy for ocular diseases |
| Q37952287 | Gene therapy for rheumatoid arthritis: current status and future prospects |
| Q26851920 | Gene therapy for the inner ear |
| Q35340196 | Gene therapy for the nervous system: challenges and new strategies |
| Q36541946 | Gene therapy for transplantation with viral vectors--how much of the promise has been realised? |
| Q38213212 | Gene therapy in India: a focus |
| Q83797705 | Gene therapy in transplantation |
| Q38243641 | Gene therapy modalities in lung transplantation. |
| Q36922247 | Gene therapy of gynaecological diseases |
| Q37207021 | Gene therapy of the rheumatic diseases: 1998 to 2008. |
| Q27007012 | Gene therapy on the move |
| Q38654544 | Gene therapy research in Asia |
| Q37515656 | Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer |
| Q37786559 | Gene therapy to the kidney using viral vectors |
| Q41807910 | Gene therapy, early promises, subsequent problems, and recent breakthroughs. |
| Q27000091 | Gene therapy: light is finally in the tunnel |
| Q37109090 | Gene therapy: some history, applications, problems, and prospects |
| Q36464907 | Gene transfer approaches for gynecological diseases |
| Q37506503 | Gene-based therapies in Parkinson's disease |
| Q35620919 | Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. |
| Q34830129 | Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. |
| Q38920465 | Genetic diseases, immunology, viruses, and gene therapy |
| Q42752947 | Genetic engineering in athletes |
| Q36423907 | Genetic medicines: treatment strategies for hereditary disorders |
| Q36288888 | Genetic modification of hematopoietic stem cells with nonviral systems: past progress and future prospects |
| Q24595921 | Genetic modification of somatic stem cells. The progress, problems and prospects of a new therapeutic technology |
| Q35925455 | Genetically engineered immune privileged Sertoli cells: A new road to cell based gene therapy |
| Q41928233 | Genome engineering: a new approach to gene therapy for neuromuscular disorders. |
| Q33781719 | Genomic and bioinformatics analysis of HAdV-4, a human adenovirus causing acute respiratory disease: implications for gene therapy and vaccine vector development |
| Q45880712 | Genomic and bioinformatics analysis of HAdV-7, a human adenovirus of species B1 that causes acute respiratory disease: implications for vector development in human gene therapy |
| Q36453658 | Genotoxicity of retroviral integration in hematopoietic cells. |
| Q37816955 | Getting arthritis gene therapy into the clinic |
| Q52314492 | Glaucoma pathogenesis and neurotrophins: Focus on the Molecular and Genetic basis for Therapeutic prospects. |
| Q26797520 | Going viral: a review of replication-selective oncolytic adenoviruses |
| Q36793856 | Haemophilia A: molecular insights. |
| Q37582126 | Helper-Dependent Adenoviral Vectors. |
| Q38302375 | Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1. |
| Q36219334 | Helper-dependent adenoviral vectors in experimental gene therapy. |
| Q33775537 | Hepatic gene transfer as a means of tolerance induction to transgene products |
| Q38712985 | Hepatocyte growth factor in dampening liver immune-mediated pathology in acute viral hepatitis without compromising antiviral activity. |
| Q38025743 | Hepatocyte transplantation for inherited metabolic diseases of the liver. |
| Q36685593 | High-level secretion of growth hormone by retrovirally transduced primary human keratinocytes: prospects for an animal model of cutaneous gene therapy. |
| Q42410618 | How to design a cell or gene therapy clinical trial: advice from the FDA. |
| Q92204445 | How to discuss gene therapy for haemophilia? A patient and physician perspective |
| Q90677465 | How will the field of gene therapy survive its success? |
| Q36672262 | Human artificial chromosome vectors meet stem cells: new prospects for gene delivery |
| Q38183464 | Human artificial chromosome-based gene delivery vectors for biomedicine and biotechnology |
| Q35238272 | Human artificial chromosomes for gene delivery and the development of animal models |
| Q44943174 | Human immunodeficiency virus vector-mediated intra-articular expression of angiostatin inhibits progression of collagen-induced arthritis in mice |
| Q35194441 | Hyaluronan-CD44 interactions as potential targets for cancer therapy. |
| Q33794201 | Hybrid lentivirus-phiC31-int-NLS vector allows site-specific recombination in murine and human cells but induces DNA damage. |
| Q40051551 | Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava |
| Q38061510 | IL-12 based gene therapy in veterinary medicine |
| Q35126751 | IL-1α and complement cooperate in triggering local neutrophilic inflammation in response to adenovirus and eliminating virus-containing cells |
| Q37291653 | Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer |
| Q38008337 | Immune recognition of gene transfer vectors: focus on adenovirus as a paradigm |
| Q42861412 | Immune regulation of transgene expression in the brain: B cells regulate an early phase of elimination of transgene expression from adenoviral vectors |
| Q36983740 | Immune responses to AAV vectors: overcoming barriers to successful gene therapy |
| Q37245006 | Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain |
| Q35882794 | Immunosuppressive exosomes: a new approach for treating arthritis |
| Q39117333 | Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques |
| Q37945219 | Improving adenovirus based gene transfer: strategies to accomplish immune evasion |
| Q90211358 | In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies |
| Q54204523 | In Vivo Gene Transfer to the Rabbit Common Carotid Artery Endothelium. |
| Q44115042 | In situ bone tissue engineering via ultrasound-mediated gene delivery to endogenous progenitor cells in mini-pigs |
| Q36105888 | In utero gene therapy: current challenges and perspectives. |
| Q39793497 | In vivo fluorescence imaging is well-suited for the monitoring of adenovirus directed transgene expression in living organisms |
| Q45889022 | In vivo gene transfer to healthy and diabetic canine pancreas. |
| Q37394036 | In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors |
| Q37416925 | Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability |
| Q35939486 | Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin |
| Q43994130 | Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors. |
| Q33977026 | Indirect imaging of cardiac-specific transgene expression using a bidirectional two-step transcriptional amplification strategy. |
| Q92999056 | Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus |
| Q33608746 | Induction of immune tolerance to FIX by intramuscular AAV gene transfer is independent of the activation status of dendritic cells |
| Q36052188 | Influence of cationic lipid concentration on properties of lipid-polymer hybrid nanospheres for gene delivery |
| Q39502394 | Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors |
| Q36237308 | Inhibition by Multifunctional Magnetic Nanoparticles Loaded with Alpha-Synuclein RNAi Plasmid in a Parkinson's Disease Model |
| Q34621683 | Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression |
| Q37499424 | Innate functions of immunoglobulin M lessen liver gene transfer with helper-dependent adenovirus |
| Q33805229 | Innate immune recognition of viruses and viral vectors |
| Q41453719 | Innate immune response after adenoviral gene delivery into skin is mediated by AIM2, NALP3, DAI and mda5. |
| Q35785201 | Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways |
| Q26997318 | Inner ear symptoms and disease: pathophysiological understanding and therapeutic options |
| Q37329603 | Insights into adenovirus host cell interactions from structural studies |
| Q39226100 | Institutional Oversight of Occupational Health and Safety for Research Programs Involving Biohazards |
| Q58199420 | Integration of ER stress and viral nucleotide sensing in DCs: Mounting a response commensurate to the threat? |
| Q39532576 | Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors |
| Q27021261 | Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer |
| Q37082190 | Interception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users |
| Q39651137 | Internalization and biodistribution of polymersomes into oral squamous cell carcinoma cells in vitro and in vivo |
| Q45862100 | Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice |
| Q37050672 | Intravenous Administration Is an Effective and Safe Route for Cancer Gene Therapy Using the Bifidobacterium-Mediated Recombinant HSV-1 Thymidine Kinase and Ganciclovir |
| Q54364641 | Intravenous injection of irradiated tumor cell vaccine carrying oncolytic adenovirus suppressed the growth of multiple lung tumors in a mouse squamous cell carcinoma model. |
| Q45863402 | Introducing Genes to the Heart: All About Delivery |
| Q99573751 | In Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model |
| Q37082159 | Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point |
| Q27318346 | Key role of splenic myeloid DCs in the IFN-alphabeta response to adenoviruses in vivo |
| Q36333340 | Large animal models and gene therapy |
| Q37778403 | Leptin gene therapy in the fight against diabetes |
| Q45883135 | Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency |
| Q37784661 | Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies |
| Q30801455 | Lipoplex structures and their distinct cellular pathways. |
| Q50763331 | Liver transplantation for urea cycle disorders in pediatric patients: a single-center experience. |
| Q37692647 | Liver, liver cell and stem cell transplantation for the treatment of urea cycle defects |
| Q45862703 | Local Vascular Gene Therapy With Apolipoprotein A-I to Promote Regression of Atherosclerosis |
| Q64378421 | Local delivery of a viral vector mitigates neutralization by antiviral antibodies and results in efficient transduction of rabbit liver |
| Q53510432 | Local osteoprotegerin gene transfer to periodontal tissue inhibits lipopolysaccharide-induced alveolar bone resorption. |
| Q45858049 | Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors. |
| Q45036081 | Long-term correction of ornithine transcarbamylase deficiency by WPRE-mediated overexpression using a helper-dependent adenovirus |
| Q51864807 | Long-term outcome following pediatric liver transplantation for metabolic disorders. |
| Q38544793 | Lung gene therapy-How to capture illumination from the light already present in the tunnel |
| Q45125275 | Luteinizing hormone plasmid therapy results in long-lasting high circulating Lh and increased sperm production in European sea bass (Dicentrarchus labrax). |
| Q39593763 | Lysosomal localization and mechanism of membrane penetration influence nonenveloped virus activation of the NLRP3 inflammasome. |
| Q37148646 | Magnetic nanoparticles as a new approach to improve the efficacy of gene therapy against differentiated human uterine fibroid cells and tumor-initiating stem cells |
| Q35952192 | Magnetically responsive biodegradable nanoparticles enhance adenoviral gene transfer in cultured smooth muscle and endothelial cells |
| Q38822218 | Management of knee osteoarthritis. Current status and future trends |
| Q37984486 | Manipulation of adenovirus interactions with host factors for gene therapy applications |
| Q33275292 | Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells |
| Q37106639 | Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets |
| Q33581506 | Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides |
| Q33684461 | Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions. |
| Q33393397 | Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses |
| Q36788494 | Medical treatment of pancreatic cancer |
| Q34676808 | Mesenchymal stem cells at the intersection of cell and gene therapy |
| Q37310677 | Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model |
| Q26741958 | Methods of Genome Engineering: a New Era of Molecular Biology |
| Q38612545 | Microbubbles and Ultrasound: Therapeutic Applications in Diabetic Nephropathy |
| Q37395452 | Microcalorimetry: a response to challenges in modern biotechnology. |
| Q40202250 | Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver |
| Q35911766 | Missing pieces in understanding the intracellular trafficking of polycation/DNA complexes |
| Q90549130 | Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing |
| Q37092541 | Modification of Schwann cell gene expression by electroporation in vivo |
| Q63928518 | Modified ARCA analogs providing enhanced translational properties of capped mRNAs |
| Q98614074 | Modified mRNA as a Therapeutic Tool for the Heart |
| Q33371239 | Modulation of TNFalpha, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors |
| Q37799373 | Molecular Mechanisms and Treatment Options for Muscle Wasting Diseases |
| Q36932523 | Molecular and macromolecular alterations of recombinant adenoviral vectors do not resolve changes in hepatic drug metabolism during infection |
| Q34667746 | Mutation of the fiber shaft heparan sulphate binding site of a 5/3 chimeric adenovirus reduces liver tropism |
| Q37241328 | Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice |
| Q40075764 | Neonatal Gene Therapy for Hemophilia B by a Novel Adenovirus Vector Showing Reduced Leaky Expression of Viral Genes |
| Q38533753 | Neprilysin gene transfer: A promising therapeutic approach for Alzheimer's disease |
| Q36356874 | Neurotrophic factor-secreting autologous muscle stem cell therapy for the treatment of laryngeal denervation injury |
| Q53262613 | New frontiers in hereditary metabolic disease: an historical perspective. |
| Q50056861 | New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy |
| Q58728426 | Non-viral Delivery of Nucleic Acids: Insight Into Mechanisms of Overcoming Intracellular Barriers |
| Q37094072 | Nonmuscle invasive bladder cancer: a primer on immunotherapy. |
| Q42615111 | Nonviral delivery of basic fibroblast growth factor gene to bone marrow stromal cells |
| Q35608449 | Novel adenovirus detected in captive bottlenose dolphins (Tursiops truncatus) suffering from self-limiting gastroenteritis. |
| Q36014074 | Novel therapies, high-risk pediatric research, and the prospect of benefit: learning from the ethical disagreements |
| Q35260938 | Novel viral vector systems for gene therapy. |
| Q33863665 | Nuclear entry of hyperbranched polylysine nanoparticles into cochlear cells |
| Q52429666 | Nuclease-Mediated Gene Therapies for Inherited Metabolic Diseases of the Liver. |
| Q60930832 | Nucleic acids and analogs for bone regeneration |
| Q37687415 | Oncolytic (replication-competent) adenoviruses as anticancer agents. |
| Q36318189 | Oncolytic adenoviruses - selective retargeting to tumor cells |
| Q35613158 | Opposite expression of CYP51A1 and its natural antisense transcript AluCYP51A1 in adenovirus type 37 infected retinal pigmented epithelial cells |
| Q35870480 | Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro |
| Q35666180 | Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity |
| Q33732824 | Optimizing cationic and neutral lipids for efficient gene delivery at high serum content |
| Q28476268 | Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems |
| Q37880689 | Organ targeted prenatal gene therapy--how far are we? |
| Q40608919 | Orthopedic gene therapy--lost in translation? |
| Q42281690 | PEGylated helper-dependent adenoviral vector expressing human Apo A-I for gene therapy in LDLR-deficient mice |
| Q33364520 | PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile |
| Q34860648 | Parenchymal expression of CD40 exacerbates adenovirus-induced hepatitis in mice. |
| Q38714311 | Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5 |
| Q30394255 | Patient-Specific Therapy via Cell-Reprogramming Technology: a Curative Potential for Patients with Diabetes |
| Q37347451 | Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems |
| Q35864258 | Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity. |
| Q39004582 | Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. |
| Q37398067 | Phenotypic correction of ornithine transcarbamylase deficiency using low dose helper-dependent adenoviral vectors |
| Q42193828 | Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor |
| Q38012709 | Phoenix rising: gene therapy makes a comeback |
| Q40510393 | Physical and infectious titers of helper-dependent adenoviral vectors: a method of direct comparison to the adenovirus reference material |
| Q33831381 | Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice |
| Q36902844 | Potential use of gene transfer in athletic performance enhancement. |
| Q38284700 | Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?. |
| Q64989716 | Precision gene editing technology and applications in nephrology. |
| Q45868822 | Preclinical evaluation of gene delivery methods for the treatment of loco-regional disease in breast cancer |
| Q37399961 | Preclinical evaluation of innate immunity to baculovirus gene therapy vectors in whole human blood |
| Q57170242 | Preclinical safety evaluation of hepatic arterial infusion of oncolytic poxvirus |
| Q56564487 | Prenatal gene therapy for the early treatment of genetic disorders |
| Q36994170 | Progress and prospects: gene therapy clinical trials (part 2). |
| Q26781432 | Progresses towards safe and efficient gene therapy vectors |
| Q33388660 | Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors |
| Q96306729 | Prospects for Cell-Directed Curative Therapy of Phenylketonuria (PKU) |
| Q40462830 | Prospects for cell-based therapy. |
| Q35824841 | Prospects for gene therapy of haemophilia |
| Q37082158 | Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse |
| Q36779377 | Prostate cancer gene therapy clinical trials |
| Q45865772 | Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. |
| Q37847687 | Pulmonary delivery of therapeutic siRNA. |
| Q35187635 | Quantification of functionalised gold nanoparticle-targeted knockdown of gene expression in HeLa cells |
| Q35069550 | Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. |
| Q63740735 | RNA Viruses as Tools in Gene Therapy and Vaccine Development |
| Q36803909 | Radionuclide reporter gene imaging for cardiac gene therapy |
| Q36878392 | Re-engineering an alphoid(tetO)-HAC-based vector to enable high-throughput analyses of gene function |
| Q27487857 | Recent Developments in Peptide-Based Nucleic Acid Delivery |
| Q89775505 | Recent advances in genome editing for cardiovascular disease |
| Q33709989 | Recent developments in gene transfer: risk and ethics |
| Q38017202 | Recent developments in transposon-mediated gene therapy |
| Q34080884 | Recognition of virus infection and innate host responses to viral gene therapy vectors |
| Q38907797 | Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models. |
| Q35772588 | Reduction of ethanol consumption in alcohol-preferring rats by dual expression gene transfer |
| Q37968572 | Regenerative nanomedicine and the treatment of degenerative retinal diseases |
| Q35847459 | Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model |
| Q34233124 | Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. |
| Q36948756 | Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself? |
| Q35575680 | Regulatory and ethical issues for phase I in utero gene transfer studies |
| Q41161224 | Reprogramming of mice primary hepatocytes into insulin-producing cells by transfection with multicistronic vectors. |
| Q35210756 | Republished review: Gene therapy for ocular diseases |
| Q34757960 | Rescuing the failing heart by targeted gene transfer |
| Q38974025 | Rethinking risk assessment for emerging technology first-in-human trials |
| Q40527438 | Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer |
| Q35224065 | SR-A and SREC-I binding peptides increase HDAd-mediated liver transduction. |
| Q46764500 | Safety assessment of intraportal liver cell application in New Zealand white rabbits under GLP conditions |
| Q39809796 | Safety studies on an adenovirus recombinant vaccine for rabies (AdRG1.3-ONRAB) in target and non-target species |
| Q34218552 | Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular disease |
| Q38920000 | Sendai virus-mediated gene transfer of the c-myc suppressor far-upstream element-binding protein-interacting repressor suppresses head and neck cancer. |
| Q37945193 | Serotype chimeric human adenoviruses for cancer gene therapy |
| Q58806285 | Sertoli Cells Engineered to Express Insulin to Lower Blood Glucose in Diabetic Mice |
| Q47353872 | Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats |
| Q49600921 | Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an AAV vector expressing human SMN. |
| Q27347215 | Sheep lung segmental delivery strategy demonstrates adenovirus priming of local lung responses to bacterial LPS and the role of elafin as a response modulator |
| Q45875060 | Shutdown of immunological priming and presentation after in vivo administration of adenovirus |
| Q90349121 | Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research |
| Q30430739 | Sonoporation: Gene transfer using ultrasound |
| Q42585087 | Special Issue: Gene Therapy with Emphasis on RNA Interference |
| Q34975214 | Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus |
| Q38124263 | Stem cells for cardiac repair: an introduction |
| Q36675446 | Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors |
| Q37503253 | Strategies to overcome host immunity to adenovirus vectors in vaccine development |
| Q45866314 | Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy |
| Q91322683 | Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization |
| Q35874710 | Sustained correction of OTC deficiency in spf( ash) mice using optimized self-complementary AAV2/8 vectors. |
| Q33826170 | Sustained expression of insulin by a genetically engineered sertoli cell line after allotransplantation in diabetic BALB/c mice |
| Q34864807 | Synergetic Targeted Delivery of Sleeping-Beauty Transposon System to Mesenchymal Stem Cells Using LPD Nanoparticles Modified with a Phage-Displayed Targeting Peptide |
| Q42137029 | Synthesis and characterization of degradable multivalent cationic lipids with disulfide-bond spacers for gene delivery |
| Q57039821 | Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy |
| Q34132297 | Systemic delivery of bioactive glucagon-like peptide 1 after adenoviral-mediated gene transfer in the murine salivary gland. |
| Q38295808 | TANK-binding kinase 1-dependent or -independent signaling elicits the cell-type-specific innate immune responses induced by the adenovirus vector |
| Q40295059 | TLR9 and IRF3 cooperate to induce a systemic inflammatory response in mice injected with liposome:DNA. |
| Q33785096 | TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses. |
| Q37209562 | Targeted gene insertion for molecular medicine |
| Q50056652 | Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency |
| Q64039369 | Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease |
| Q39298850 | Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice |
| Q27653315 | The Cell Adhesion Molecule “CAR” and Sialic Acid on Human Erythrocytes Influence Adenovirus In Vivo Biodistribution |
| Q53065419 | The Death of Jesse Gelsinger: New Evidence of the Influence of Money and Prestige in Human Research |
| Q34975228 | The challenge for gene therapy: innate immune response to adenoviruses |
| Q47910262 | The ethics of human gene transfer |
| Q38189250 | The evolution of adenoviral vectors through genetic and chemical surface modifications |
| Q30053630 | The evolution of gene therapy in X-linked severe combined immunodeficiency |
| Q34132804 | The future potential for cocaine vaccines |
| Q34220590 | The potential of nanomedicine therapies to treat neovascular disease in the retina. |
| Q36674594 | The role of Rds in outer segment morphogenesis and human retinal disease |
| Q37998186 | The role of normothermic extracorporeal perfusion in minimizing ischemia reperfusion injury. |
| Q45144005 | The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer |
| Q41627004 | The spread of adenoviral vectors to central nervous system through pathway of cochlea in mimetic aging and young rats |
| Q45873891 | Therapeutic RNA silencing of Cys-X3-Cys chemokine ligand 1 gene prevents mice from adenovirus vector-induced acute liver injury |
| Q34982869 | Therapeutic approaches to muscular dystrophy. |
| Q37866086 | Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges |
| Q45886566 | Therapeutic lentivirus-mediated neonatal in vivo gene therapy in hyperbilirubinemic Gunn rats |
| Q92749886 | Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy |
| Q37809086 | Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators |
| Q36549699 | Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy. |
| Q36066048 | Therapy for haemophilia: recent advances and goals for the future |
| Q37274356 | Tissue engineering for bone defect healing: an update on a multi-component approach |
| Q35779378 | Tissue-specific promoters for cancer gene therapy |
| Q33633293 | Toward Personalized Gene Therapy: Characterizing the Host Genetic Control of Lentiviral-Vector-Mediated Hepatic Gene Delivery |
| Q45858373 | Toward gene therapy for hemophilia A with novel adenoviral vectors: successes and limitations in canine models |
| Q44104372 | Transcriptional activities of the Sleeping Beauty transposon and shielding its genetic cargo with insulators. |
| Q53826123 | Transduction Properties of Adenovirus Serotype 35 Vectors After Intravenous Administration Into Nonhuman Primates. |
| Q51766318 | Transfection of cells using flow-through electroporation based on constant voltage. |
| Q37077838 | Transfer of human artificial chromosome vectors into stem cells |
| Q40225778 | Transgene Expression in Dogs After Liver-Directed Hydrodynamic Delivery of Sleeping Beauty Transposons Using Balloon Catheters |
| Q42223027 | Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver |
| Q47697784 | Transplantation as disease modifying therapy in adults with inherited metabolic disorders |
| Q37714129 | Transplantation of betatrophin-expressing adipose-derived mesenchymal stem cells induces β-cell proliferation in diabetic mice |
| Q34183436 | Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. |
| Q40297448 | Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells |
| Q33654083 | Uptake and transfection efficiency of PEGylated cationic liposome-DNA complexes with and without RGD-tagging |
| Q38181868 | Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases |
| Q35240986 | Use of genetically modified muscle and fat grafts to repair defects in bone and cartilage |
| Q26786070 | Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery |
| Q30433085 | V(alpha)14iNKT cells promote liver pathology during adenovirus infection by inducing CCL5 production: implications for gene therapy |
| Q44236123 | Vector-related tumorigenesis not found in ornithine transcarbamylase-deficient mice |
| Q36780050 | Vectors for airway gene delivery |
| Q35665175 | Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer |
| Q39149034 | Viral Vector Biosafety in Laboratory Animal Research |
| Q26741952 | Viral Vectors for Gene Therapy: Current State and Clinical Perspectives |
| Q55408780 | Viral Vectors in Gene Therapy. |
| Q34315475 | Viral and nonviral delivery systems for gene delivery |
| Q37687420 | Viral vector-mediated gene transfer for CNS disease |
| Q37262766 | Viral vectors: from virology to transgene expression |
| Q42579980 | Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo |
| Q35260293 | Virus infection recognition and early innate responses to non-enveloped viral vectors |
| Q39594815 | Visualization of intracellular trafficking of Math1 protein in different cell types with a newly-constructed nonviral gene delivery plasmid |
| Q58554739 | Whatever happened to the Shwartzman phenomenon? |
| Q53320095 | [Clinical application of gene therapy. Previous experience and the future]. |
| Q37035388 | microRNAs: a new emerging class of players for disease diagnostics and gene therapy |
| Q40053389 | piggyBac as a high-capacity transgenesis and gene-therapy vector in human cells and mice |
| Q40035650 | siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma |
| Q37679521 | β-globin matrix attachment region improves stable genomic expression of the Sleeping Beauty transposon |
Search more.